Literature DB >> 709521

The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma.

S A Wells, D E Haagensen, W M Linehan, R E Farrell, W G Dilley.   

Abstract

Plasma levels of carcinoembryonic antigen (CEA) and calcitonin (CT) were measured in 35 normal control subjects and in 37 patients with suspected or established medullary thyroid carcinoma (MTC). None of the normal control subjects had elevated basal plasma levels of either CEA (greater than 5 ng/ml) or CT (greater than 0.25 ng/ml). However, of the 37 patients with suspected or established MTC, 23 (62%) had elevated basal plasma levels of CEA (range 9.8--7,000 ng/ml) and 27 (73%) had elevated basal plasma CT values (range 0.30--500 ng/ml). Generally, patients with clinically apparent MTC, either primary or metastatic, had higher plasma CEA and CT levels than those with occult disease. A positive correlation was found (r = 0.785, p less than 0.01) when comparing basal plasma CEA and stimulated plasma CT levels in 20 patients. A marked increase above the basal plasma level of CT but not CEA was detected in each of six MTC patients following intravenous calcium or pentagastrin. These data demonstrate that basal plasma levels of CEA and CT were increased in a large percentage of patients with MTC. Plasma calcitonin levels unlike plasma CEA levels were more often elevated in patients with occult disease and were increased above basal following the intravenous administration of either calcium gluconate or pentagastrin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 709521     DOI: 10.1002/1097-0142(197809)42:3+<1498::aid-cncr2820420821>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.

Authors:  C M Thomas; S L Asa; S Ezzat; A M Sawka; D Goldstein
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?

Authors:  Per Bümming; Håkan Ahlman; Bengt Nilsson; Ola Nilsson; Bo Wängberg; Svante Jansson
Journal:  Langenbecks Arch Surg       Date:  2008-07-15       Impact factor: 3.445

Review 4.  Medullary thyroid cancer: medical management and follow-up.

Authors:  Amber Traugott; Jeffrey F Moley
Journal:  Curr Treat Options Oncol       Date:  2005-07

5.  Medullary carcinoma of the thyroid gland.

Authors:  C Russell
Journal:  Ulster Med J       Date:  1980

Review 6.  A Review of the Significance in Measuring Preoperative and Postoperative Carcinoembryonic Antigen (CEA) Values in Patients with Medullary Thyroid Carcinoma (MTC).

Authors:  Ioannis Passos; Elisavet Stefanidou; Soultana Meditskou-Eythymiadou; Maria Mironidou-Tzouveleki; Vasiliki Manaki; Vasiliki Magra; Styliani Laskou; Stylianos Mantalovas; Stelian Pantea; Isaak Kesisoglou; Konstantinos Sapalidis
Journal:  Medicina (Kaunas)       Date:  2021-06-11       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.